22.08.2019, Basel, Switzerland
Over subsequent months, the agency launched a brace of RWE initiatives, including a $100 M project to collect RWE data from 10 M individuals, an app for the collection of real-world data (RWD), partnerships for cancer research using RWE, and, most crucially, their 2019 strategic Framework on the use of RWD and RWE.
RWE as more than a "valuable complement"
What this demonstrates is, as more patient data is digitized and as more evidence is collected on RWE itself, that the value of RWE in generating insights into a drug’s impact on patient journeys and outcomes is now fully accepted and beginning to be actionable.
Besides being a valuable complement to evidence from traditional randomized controlled trials, RWE can support assessments of treatment patterns, costs and outcomes of interventions, identify underserved therapeutic areas, and assess efficacy or safety of therapies in real-world use. In particular, RWE can be used to design efficient trials, support market access activities and inform reimbursement decisions.
Supporting the next generation of clinical researchers
Clinerion supports improving patient outcomes via real world evidence. Today, our Patient Network Explorer offers analytics based on de-identified real-world data from 20 million patients around the world from our global network of partner hospitals.
We are excited to “pay it forward” and support the development of the next generation of clinical researchers.
To this end, Clinerion is partnering with Dresden International University to offer their Master’s in Clinical Research students access to a subset of our real-world data.
These students will gain unprecedented insights and generate valuable, actionable real-world evidence through the use of our real-time, real-world data in their research. We look forward to the world of advances in learning that will arise from these clinicians and investigators of the future!
Read more about our new RWE initiative with Dresden International University >
